Does stage II colorectal cancer need to be redefined?

Clinical Cancer Research

Volumn 17, Issue 10, 2011, Pages 3053-3055

  Grothey, Axel ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; GUANYLATE CYCLASE; GUANYLATE CYCLASE 2C; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER STAGING; COLON CARCINOGENESIS; COLORECTAL CANCER; DISEASE FREE SURVIVAL; HUMAN; LYMPH NODE METASTASIS; NONHUMAN; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR RECURRENCE;

CARCINOMA; COLORECTAL NEOPLASMS; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MODELS, BIOLOGICAL; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; RECEPTORS, GUANYLATE CYCLASE-COUPLED; RECEPTORS, PEPTIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 79956002818     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0574     Document Type: Article

References (12)

1. Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA. Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer. Clin Cancer Res 2011;17:3293-303.
2. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart A. Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol 2010;28:256-63.
3. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 2010;28:264-71.
4. Grothey A. Adjuvant chemotherapy in colon cancer-is it worth it? Eur J Cancer 2010;46:1768-9.
5. O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 2010;28:3937-44.
6. Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011;29:17-24.
7. Basu N, Arshad N, Visweswariah SS. Receptor guanylyl cyclase C (GC-C): regulation and signal transduction. Mol Cell Biochem 2010;334:67-80.
8. Mann EA, Steinbrecher KA, Stroup C, Witte DP, Cohen MB, Giannella RA. Lack of guanylyl cyclase C, the receptor for Escherichia coli heat-stable enterotoxin, results in reduced polyp formation and increased apoptosis in the multiple intestinal neoplasia (Min) mouse model. Int J Cancer 2005;116:500-5. (Pubitemid 41099184)
9. Li P, Schulz S, Bombonati A, Palazzo JP, Hyslop TM, Xu Y, et al. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology 2007;133:599-607. (Pubitemid 47187356)
10. Waldman SA, Hyslop T, Schulz S, Barkun A, Nielsen K, Haaf J, et al. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA 2009;301:745-52.
11. Andre T, Shi Q, Yothers GA, Bot BM, Haller DG, Van Cutsem E, et al. Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS)-Findings from the ACCENT dataset. J Clin Oncol 2010;28:15s(suppl; abstr 3616).
12. Sargent D, Shi Q, Bot B, Resnick M, Meyers M, Goldar-Najafi A, et al. GCC expression in lymph nodes as a significant determinant of recurrence in stage II colon cancer patients. J Clin Oncol 2011;29: (suppl 4);369.